First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

First Wave BioPharma, a clinical-stage biopharmaceutical company specializing in gastrointestinal (GI) diseases, has announced that the final patient has been dosed in the Phase 2 SPAN clinical trial. The trial is investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients. Topline..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

First Wave BioPharma Strengthens Intellectual Property Estate

First Wave BioPharma, a clinical-stage biopharmaceutical company specializing in gastrointestinal (GI) diseases, has announced the publication of two patent applications for its enhanced enteric microgranule delivery formulation of adrulipase. The patents cover composition of matter and methods of use claims and were published by both the United States Patent and Trademark Office (USPTO) and the..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 28.
  • textsms